Concurrent Presentation of Eczema Herpeticum and Acute Localized Exanthematous Pustulosis in a Patient With Atopic Dermatitis: A Rare Dermatological Convergence

TL;DR

A rare case of two skin conditions, eczema herpeticum and ALEP, occurring together in a patient with atopic dermatitis is reported, highlighting the complexity of diagnosis and treatment.

Contribution

This is the first documented case of concurrent eczema herpeticum and acute localized exanthematous pustulosis in a patient with atopic dermatitis.

Findings

The patient initially treated with ceftaroline developed ALEP-like pustules.

Switching to linezolid led to the complete resolution of both conditions.

The case emphasizes the need for tailored therapeutic strategies in complex dermatological scenarios.

Abstract

Eczema herpeticum (EH) is a severe and potentially life-threatening viral infection occurring in individuals with preexisting eczema or atopic dermatitis. It is primarily caused by the herpes simplex virus, presenting as painful vesicular eruptions on the skin. On the other hand, acute localized exanthematous pustulosis (ALEP) is a rare variant of acute generalized exanthematous pustulosis (AGEP), characterized by the sudden onset of localized, nonfollicular pustules on an erythematous base. It is often triggered by recent medication administration, and its clinical presentation mimics AGEP, although ALEP exhibits a confined distribution of pustules. Prompt diagnosis and identification of the offending agent are crucial for effective management. Both are distinct cutaneous manifestations that rarely occur concurrently, presenting unique diagnostic and therapeutic challenges.

We present the first documented case of coexisting ALEP and EH in a 32-year-old male with a history of atopic dermatitis. The patient was admitted with features suggestive of EH, including vesicular lesions over the face, along with a positive Methicillin-resistant Staphylococcus aureus (MRSA) swab. Treatment with ceftaroline initially initiated resulted in the development of localized pustules, indicative of ALEP. Transition to linezolid led to the complete resolution of both conditions, marking a compelling recovery. The distinctive interplay between EH, ALEP, and AGEP presents a novel challenge, emphasizing the need for nuanced clinical assessment and tailored therapeutic strategies. This case offers crucial insights into the intricate relationship between medication-induced dermatological conditions and underlying cutaneous vulnerabilities. This unprecedented case highlights the rarity and complex management nuances associated with the simultaneous occurrence of ALEP and EH. The successful resolution following medication adjustments underscores the need for flexibility and comprehensive evaluation in addressing such intricate dermatological scenarios, providing valuable insights into potential synergies between distinct cutaneous conditions.

Figures